RIDGELAND, Miss., Aug. 22, 2005 (PRIMEZONE) -- Knobias, Inc. (OTCBB:KNBS) announced today that it has selected CRYO-CELL International, Inc. (OTCBB:CCEL) as the SPOT of the week in the Knobias Small-Cap "ClipReport."
CRYO-CELL International, Inc. is the world's largest umbilical cord stem cell banking firm, offering high-quality cord blood preservation exclusively for the benefit of newborn babies and other family members. CCEL is accredited by the AABB and operates in a newly constructed state-of-the-art current "Good Manufacturing Practice and Good Tissue Practice" (cGMP/cGTP) compliant facility.
The Bulls say...
-- Stem Cell Hype: Stem cell research sparks heated debates surrounding morality vs. promise, but many are unaware of the more "non-controversial" side of this topic. On 05/24/05, the U.S. House passed (430-1) bill HR-2520 to allocate $79 million for a national inventory of 150,000 cord blood units for transplantation. HR-2520 is expected to pass the Senate and the administration has stated that it, "...strongly supports House passage of HR 2520...encourages efforts to seek ethical ways to pursue stem cell research..." CCEL believes it could benefit from this bill on "multiple dimensions."
The Bears say...
-- Relative Growth Rate: CCEL has steady growth, but competitors may have an edge on growth rate. CCEL FY04 sales grew 62 percent but Q2 only grew 12 percent. VIAC grew FY04 sales by 20 percent; Q2 sales up 18 percent. CBAI has not reported Q2, but showed 200 percent sales growth in FY04.
The "ClipReport" is a daily newsletter distributed FREE to anyone interested in proprietary news and insight concerning small-, micro- and nano-cap stocks. Each week Knobias independently chooses one company to be highlighted in the SPOT. To qualify for selection, each company must: 1) trade on the Nasdaq National Market, Nasdaq Smallcap Market, Amex, OTCBB or Pink Sheets; 2) have a Market cap of less than $250 million; 3) have annual revenues greater than $1 million, 4) have a closing share price greater than 5 cents, and 4) have average daily volume of at least 10,000 shares. Knobias is never compensated for SPOT selections, and NO position will be held in SPOT stocks by Knobias, its management or staff while the stock is being highlighted.
To subscribe to the FREE Knobias Small-Cap "ClipReport", click below: http://www.knobias.com/clipreport.
For advertising information concerning the Knobias Small-Cap "ClipReport", submit requests to: sales@knobias.com.
For information concerning Knobias Issuer Services Program, submit requests to: sales@knobias.com.
About Knobias, Inc.
Knobias, Inc. provides complete financial information solutions for institutional market participants, corporations and industry professionals. By receiving early and accurate proprietary information, our clients are allowed to monitor and trade more successfully. Actionable data is delivered via high-quality applications consisting of proprietary products; analytics; streaming information; financial data; fundamental research; and third-party research. Whether you are interested in small cap or the broader markets, we have the tools, information and knowledge you need. For more information about Knobias, Inc. products, please visit www.knobias.com
Forward-Looking Safe Harbor Statement
To the extent that this release discusses any expectations concerning future plans, financial results or performance, such statements are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and are subject to substantial risks and uncertainties. Actual results could differ materially from those anticipated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and reflect only management's belief and expectations based upon presently available information. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Knobias assumes no obligation to update any of the forward-looking statements in this release.